Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OLX301D

            Therapeutic Area: Ophthalmology Product Name: OLX301D

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: OliX Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 16, 2020


            Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.